Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HANSOH PHARMA Ameile's Two New Indications Included in China's NRDL
Recommend 1 Positive 5 Negative 0 |
||||
|
||||
|
HANSOH PHARMA (03692.HK) announced that two new indications of Ameile, an innovative drug of the Group, have been successfully added to the new National Reimbursement Drug List (2025 Version) (2025 NRDL), and all indications of Saint Luolai and Hengmu, innovative drugs of the Group, have been renewed in the 2025 NRDL. The new NRDL will be officially implemented on January 1, 2026. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
